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Background: MicroRNAs (miRNAs) are short, non-coding RNA molecules that act as regulators of gene expression.
Circulating blood miRNAs offer great potential as cancer biomarkers. The objective of this study was to correlate
the differential expression of miRNAs in tissue and blood in the identification of biomarkers for early detection of
colorectal cancer (CRC).
Methods: The study was divided into two phases: (I) Marker discovery by miRNA microarray using paired
cancer tissues (n = 30) and blood samples (CRC, n = 42; control, n = 18). (II) Marker validation by stem-loop
reverse transcription real time PCR using an independent set of paired cancer tissues (n = 30) and blood
samples (CRC, n = 70; control, n = 32). Correlation analysis was determined by Pearson’s test. Logistic
regression and receiver operating characteristics curve analyses were applied to obtain diagnostic utility of
the miRNAs.
Results: Seven miRNAs (miR-150, miR-193a-3p, miR-23a, miR-23b, miR-338-5p, miR-342-3p and miR-483-3p)
have been found to be differentially expressed in both tissue and blood samples. Significant positive
correlations were observed in the tissue and blood levels of miR-193a-3p, miR-23a and miR-338-5p. Moreover,
increased expressions of these miRNAs were detected in the more advanced stages. MiR-193a-3p, miR-23a
and miR-338-5p were demonstrated as a classifier for CRC detection, yielding a receiver operating
characteristic curve area of 0.887 (80.0% sensitivity, 84.4% specificity and 83.3% accuracy).
Conclusion: Dysregulations in circulating blood miRNAs are reflective of those in colorectal tissues. The triple
miRNA classifier of miR-193a-3p, miR-23a and miR-338-5p appears to be a potential blood biomarker for early
detection of CRC.
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Colorectal cancer (CRC) is the third most common cancer
worldwide, with an estimation of 1.2 million new cases
per year and more than 600,000 deaths [1-3]. The risk of
CRC increases with age, whereby most cases are diag-
nosed in individuals aged 50 and above [4]. Incidence rate
of CRC has been increasing in Asian countries. In
Malaysia, it ranks the second after lung cancer and breast
cancer in men and women, respectively [5]. The 5-year* Correspondence: flyong88@yahoo.com
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reproduction in any medium, provided the orsurvival rate exceeds 90% when CRC is detected at an
early, localized stage [6]. However, most cases are diag-
nosed at late stages due to inconvenient settings of current
CRC screening tests and low population compliance. Col-
onoscopy has significant contribution in the detection of
neoplastic lesions, but the requirements of bowel prepa-
ration, sedation and invasive nature have hindered its
widespread application as a screening tool [7]. Other
structural tests such as computed tomographic colono-
graphy and double contrast barium enema are limited
by the concern of radiation exposure and cost [8].
Fecal-based analyses such as occult blood, immuno-
chemical and stool DNA tests are common noninvasivetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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low sensitivity and specificity against detection of pre-
malignant lesions [10,11]. Although stool DNA test
utilizes molecular markers such as KRAS, APC and
TP53 genes as detection targets, it is not favorably
recommended by the US Preventive Service Task Force
due to high cost, uncertainty of test performance and
labor-intensive handling [12-14]. Thus, there is an
imperative need for other noninvasive biomarkers to
complement and improve current diagnostic and prog-
nostic tools in CRC.
MicroRNAs (miRNAs) are short (19–22 nucleotides),
non-coding RNA molecules that act as regulators of
gene expression [15]. Although their main mechanism of
action is through mRNA degradation or translational
inhibition, they can also induce gene activation [16,17].
The pioneer discovery of miRNAs was initiated by Lee
and colleagues in 1993 when they found lin-4, a small
RNA molecule that was capable of controlling the larval
development of Caenorhabditis elegans [18]. Since then,
a vast number of miRNAs have been reported. To date,
there are more than 2000 entries of human miRNAs in
the miRNA database, miRBase 19.0, constituting around
1% of total genes that can regulate up to one third of
human genome [19]. MiRNAs are evolutionary con-
served across species and expressed in a tissue-specific
manner [20]. They have been determined to play
important roles in cancer pathophysiology such as cell
proliferation, differentiation, apoptosis and metastasis
[21-23]. MiRNA genes are frequently located at fragile
sites and genomic regions of deletion and amplification
implicated in cancers [24,25]. They can confer both onco-
genic and tumor suppressive roles, depending upon their
downstream targets [26-28]. MiRNAs are detectable in
tissues, blood, feces and other body fluids such as saliva,
tears and urine [29-32]. The presence of miRNAs in the
circulation system is mediated via exosome transfer to
the surrounding microenvironment [33,34]. Blood-based
miRNA profiling has become a favorable area of research
for the identification of noninvasive biomarkers in can-
cers and other diseases [35-38]. In addition, a study by
Heneghan et al. reported a strong preference of using
whole blood to serum or plasma for systemic miRNAs
detection and quantification [39]. Circulating blood
miRNAs are generally Ago-bound and protected from en-
dogenous RNases that enable them to serve as stable blood
biomarkers [40,41].
An important concern for utilization of miRNAs as
biomarkers is whether the dysregulated miRNAs are
related to CRC alone or as a general mechanism in
histologic progression to cancer [29,42]. The objective of
this study was to correlate the differential expression of
miRNAs in tissue and blood in the identification of
biomarkers for early detection of CRC.Methods
Study design and sample selection
A case–control study was designed to identify blood
miRNAs that are reflective of those in colorectal tissues.
This study was performed with the approval from Medical
Ethics Committee of University of Malaya Medical Centre
(UMMC) (reference number 805.9). A total of 162 partici-
pants were enrolled from January 2011 to January 2013 at
UMMC. A number of 112 blood samples and a subset of
60 paired cancer tissues with adjacent normal mucosa
were collected from primary CRC patients. The histology
was confirmed by pathological analysis and staged accor-
ding to the tumor-node-metastasis (TNM) staging system
of the International Union Against Cancer. For the control
group, 50 blood samples were collected from individuals
who were proven to be colonic disease-free after colonos-
copy. They were matched to the CRC patients according
to age, gender and race. Written informed consent has
been obtained from each participant. The tissue and
whole blood samples were collected in tubes containing
RNAlater (Ambion, Austin, TX).
Total RNA isolation
Total RNA (including miRNAs) from tissue and blood
samples were extracted using Qiagen miRNeasy Mini
Kit (Qiagen, Valencia, CA) and Ribopure Blood RNA
Isolation Kit (Ambion) respectively, according to manu-
facturer’s instructions. RNA concentration and integrity
were determined using NanoDrop 2000 Spectrophotom-
eter (Thermo Scientific Wilmington, DE) and Agilent
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA).
RNA samples with the RNA integrity number ≥ 7.0 and
the absence of DNA contamination were used for down-
stream experiments [43].
MiRNA microarray expression profiling and analysis
The miRNA expression profiles were generated by
GeneChip miRNA 2.0 Array (Affymetrix, Santa Clara,
CA). This array contains 15,644 probe sets, covering 131
organisms and detecting 1,105 human mature miRNAs.
The content is derived from Sanger miRBase miRNA
database version 15.0. Briefly, 1 μg of total RNA was
biotin-labeled using 3DNA Array Detection Flashtag
Biotin HSR RNA Labeling Kit (Genisphere LLC, Hatfield,
PA). The samples were hybridized overnight in Affymetrix
Hybridization Oven 640, washed and stained using
Affymetrix Fluidics Station 450 and scanned with Gene-
Chip Scanner 3000 7G. Cell intensity file was generated in
the GeneChip Command Console software and used for
further analysis with GeneSpring GX 12.0 (Agilent Tech-
nologies). Robust multichip averaging (RMA) algorithm
was applied for background correction and probe sum-
marization of perfect match values in each microarray
chip. Median intensity values for each miRNA from the
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normalization to normalize the data across different arrays
[44]. The normalized data were analyzed using t-test/
ANOVA analysis with p value computations done asymp-
totically at p < 0.05. Subsequently, the gene lists were
filtered at a fold change cut-off of 1.5. Hierarchical cluste-
ring was computed using similarity measure of Euclidean
distance and average linkage rule and expressed in the
form of heat map and three dimensional (3D) principal
component analysis (PCA) plot. The miRNA microarray
data reported are MIAME compliant and have been sub-
mitted to the NCBI Gene Expression Omnibus (GEO)
database (Accession: GSE39845).
Two independent miRNA microarray profiling studies
of tissue and blood were conducted. In tissue miRNA
array, 30 paired cancer tissue and the adjacent normal mu-
cosa samples were pooled according to stages II (n = 10),
III (n = 10) and IV (n = 10), respectively. In blood miRNA
array, blood samples from 42 CRC cases were grouped by
tumor location (colon; rectum) and pooled into stages I
(n = 3; n = 3), II (n = 9; n = 3), III (n = 9; n = 3) and IV (n = 9;
n = 3). Blood samples from 18 healthy controls were used
for the profiling study. Due to limited availability of stage I
CRC cases, only one replicate was performed for both
colon and rectal samples. Similarly, the profiling analyses
of rectal samples for stages II, III and IV were also
performed in one replicate. On the other hand, the profil-
ing analyses of stages II, III and IV of colon samples were
performed in triplicates and control samples in six repli-
cates, with n = 3 each. The blood samples were obtained
from the same group of patients who have donated their
tissue samples. The tissue and blood miRNA profiles were
then correlated and used to determine the miRNAs that
were concurrently expressed.
Stem-loop reverse transcription real time PCR (RT-PCR)
assay
The miRNA microarray results were validated with
stem-loop RT-PCR using Taqman MicroRNA Assay
on StepOnePlus Real Time PCR system (Applied
Biosystems, Foster City, CA). An independent set of 30
paired cancer tissues (stage II, n = 10; stage III, n = 10;
stage IV, n = 10), 70 blood samples from CRC patients
(stage I, n = 19; stage II, n = 20; stage III, n = 19; stage IV,
n = 12) and 32 blood samples from healthy controls were
used in the validation study. This is a two-step protocol
which utilizes reverse transcription with miRNA-specific
primer followed by quantitative real time PCR with
Taqman probe. Seven miRNAs were selected for this
purpose and the primer sequences are listed in Additional
file 1. Briefly, total RNA of 10 ng was subjected to reverse
transcription using Taqman MicroRNA RT Kit which
comprised of 100 mM dNTPs, 50 U/ul Multiscribe
Reverse Transcriptase, 10X RT Buffer and 20 U/ul RNaseInhibitor (Applied Biosystems). The RT product was then
diluted at 1:15 dilution and added to the reaction mixture
of Taqman 2X Fast Advanced Master Mix and Taqman
20X MicroRNA Assay for RT-PCR. All assays were
performed in triplicate and adhered to the protocols
provided by the manufacturer. The expression of each
miRNA relative to RNU48 as endogenous control was
presented as ΔCT. A Ct value of 35 was set as the cut-
off value for defining as non-detected [45,46]. Fold
change was determined using comparative CT (2-ΔΔCT)
method [47].
Statistical analysis
The patients’ demographics were reported as mean ±
standard deviation or frequencies and percentages for
continuous and categorical variables, respectively.
Microarray data analysis was carried out as outlined
above. T-tests were used to determine the level of sig-
nificance (p < 0.05) of the selected miRNAs. Correlation
analysis was determined by Pearson’s test. Logistic
regression and receiver operating characteristics (ROC)
curve analyses were applied to obtain diagnostic utility
of the miRNAs. Statistical analysis was performed using




A total of 112 CRC patients and 50 healthy controls
were enrolled in this study (Table 1). No significant
differences were observed between the CRC patients and
controls in the distribution of age (p = 0.071, chi-square
test) and gender (p = 0.174, Fisher’s exact test). Malaysia
is comprised of a multi-ethnic population. The National
Cancer Registry of Malaysia has reported a higher
proportion of CRC cases in the Malaysian Chinese
population [5]. Thus, approximately 52% of the samples
obtained were from the Malaysian Chinese and the
remainders were from the Malays and Malaysian Indians
(p = 0.202, Fisher’s exact test). All CRC cases in this
study were adenocarcinomas. The characteristics of the
subset of 60 paired cancer tissues with adjacent normal
mucosa were listed in Table 2.
Tissue and blood miRNA microarray profiling
In the discovery of global miRNA expression in cancer
tissue and whole blood, two independent miRNA
profiles were generated. Hierarchical clustering analyses
of the tissue and blood arrays were shown in Figures 1A
and 1B, respectively. The heat maps indicated the
number of miRNAs that were differentially regulated
between the normal/control group versus the cancer
group. Moreover, differential expressions of the miRNAs
were observed among samples of different TNM staging.
Table 1 Patients’ demographics: characteristics of CRC










Average age (years) 64.4 ± 9.0 61.5 ± 9.3 0.071
Gender Male 67 (59.8%) 24 (48.0%) 0.174
Female 45 (40.2%) 26 (52.0%)
Race Malay 26 (23.2%) 15 (30.0%) 0.202
Chinese 64 (57.1%) 21 (42.0%)
Indian 22 (19.6%) 14 (28.0%)




Tumor location Colon 72 (64.3%)
Rectum 40 (35.7%)
Tumor grading G1 25 (22.3%)
(adenocarcinoma) G2 76 (67.9%)
G3 11 (9.8%)
ap value for age was calculated by chi-square test; p values for gender and
race were calculated by Fisher’s exact test.
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control samples have been determined to be highly
expressed in CRC samples. At the fold change cut-off of
1.5, the tissue miRNA array revealed 40 significantly up-
regulated miRNAs and 32 down-regulated miRNAs
(Additional file 2A). On the other hand, the bloodTable 2 Patients’ demographics: characteristics of the
subset of paired cancer tissue from CRC patients
Characteristics Subset of paired cancer tissue
(n = 60), n (%)
Average age (years) 63.8 ± 10.6
Gender Male 33 (55.0%)
Female 27 (45.0%)
Race Malay 10 (16.7%)
Chinese 38 (63.3%)
Indian 12 (20.0%)




Tumor location Colon 60 (100.0%)
Rectum 0
Tumor grading G1 13 (21.7%)
(adenocarcinoma) G2 43(71.7%)
G3 4 (6.7%)miRNA array only revealed 15 significantly up-regulated
and 9 down-regulated miRNAs (Additional file 2B).
Next, 3D PCA plots were computed to provide visual
representations of the samples. The 3D PCA plot dis-
tributes the samples into a three dimensional space
based on variance in miRNA gene expressions. Samples
from the same group and stage were found to be
clustered together in distinctive patterns, as shown in
the Figure 1C and 1D, respectively.
The tissue array revealed a higher number of dere-
gulated miRNAs and those that were concurrently
expressed in blood array were selected for further valid-
ation (Figure 2). The selected miRNAs consisted of two
down-regulated (miR-150 and miR-342-3p) and five up-
regulated miRNAs (miR-193a-3p, miR-23a, miR-23b,
miR-338-5p and miR-483-3p).
Validation of miRNA expressions by RT-PCR
The selected miRNAs from miRNA profiling were vali-
dated with RT-PCR using an independent set of tissue
and blood samples. RNU48 was chosen as the endoge-
nous control in data normalization and its expression
was found to be stable and reproducible. No significant
difference was found in the level of RNU48 (p = 0.483)
between CRCs and controls. Using a new subset of 30
paired cancer tissue and adjacent normal mucosa sam-
ples, significant deregulations were noticed in the panel
of seven miRNAs using paired t-test (p = 0.039 for miR-
150, p = 0.037 for miR-193a-3p, p = 0.031 for miR-23a,
p = 0.025 for miR-23b, p = 0.023 for miR-338-5p, p = 0.025
for miR-342-3p, p = 0.009 for miR-483-3p). For blood
samples validation, significant elevations were detected in
the levels of miR-193a-3p (p < 0.001), miR-23a (p = 0.043),
miR-23b (p = 0.045), miR-338-5p (p < 0.001) and miR-483-
3p (p = 0.010) in CRC cases. However, no significant dif-
ference was observed in the levels of miR-150 (p = 0.450)
and miR-342-3p (p = 0.560). The absolute Ct values of
miRNAs in both tissue and blood samples ranged from 21
to 28 for miR-150, 27 to 33 for miR-193a-3p, 23 to 30 for
miR-23a, 23 to 31 for miR-23b, 28 to 33 for miR-338-5p,
25 to 29 for miR-342-3p and 26 to 33 for miR-483-3p.
Relationship between tissue and blood miRNAs
Given that miR-193a-3p, miR-23a, miR-23b, miR-338-5p
and miR-483-3p were significantly up-regulated in both
tissue and blood samples from the validation study, we
have proceeded to investigate the correlation between
them. The purpose is to provide a stronger confirmation
that deregulated miRNA expressions in the systemic
circulation are potential indicators of what is happening at
tissue level. Controlling for age, gender, race and TNM
staging, correlation analyses between tissue and blood RT-
PCR data for miR-193a-3p (r = 0.811, p < 0.001), miR-23a
(r = 0.827, p < 0.001), miR-23b (r = 0.044, p = 0.818),
Figure 2 Venn diagram of differentially expressed miRNAs in
tissue and blood arrays. Down-regulated miRNAs were indicated
in green while up-regulated miRNAs were indicated in red.
Figure 1 Hierarchical clustering and PCA analyses. (A) Tissue miRNA array. Data were expressed as fold change of cancer tissue versus
adjacent normal mucosa. (B) Blood miRNA array. Data were expressed as fold change of TNM stages (I, II, III and IV) versus healthy controls. S1,
stage I; S2, stage II; S3, stage III; S4, stage IV. Green: down-regulation; red: up-regulation. (C) PCA plot of paired cancer tissue and adjacent normal
mucosa samples. Color by type, red: cancer tissue; blue: adjacent normal mucosa. (D) PCA plot of whole blood samples. Color by type, red:
control; blue: stage I; brown: stage II; grey: stage III; green: stage IV.
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(r = 0.373, p = 0.042) were conducted. The results indi-
cated significant positive correlations in the levels of miR-
193a-3p, miR-23a and miR-338-5p between tissue and
blood samples. MiR-23b was not significantly correlated
while miR-483-3p revealed weak correlation. Thus, miR-
193a-3p, miR-23a and miR-338-5p were selected as the
triple miRNA classifier in our study. Moreover, an increas-
ing trend of expression was observed in these circulating
blood miRNAs from the less advanced stages (I and II) to
the more advanced stages (III and IV) when compared
with controls (p < 0.05) (Figure 3A, 3B and 3C).
Diagnostic value of the triple miRNA classifier: miR-193a-3p,
miR-23a and miR-338-5p in CRC
The predictive performance of individual circulating blood
miRNA and the triple miRNA classifier for defining CRC
were demonstrated by multivariate logistic regression
Figure 3 Expression levels of circulating blood (A) miR-193a-3p, (B) miR-23a and (C) miR-338-5p. An increasing trend of expression was
observed in the circulating blood miRNAs in the more advanced stages when compared with controls. Statistically significant differences were
tested at *p < 0.05. MiRNA expression was presented as fold change (2-ΔΔCT); error bars represent mean ± SEM.
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Table 3 Multivariate logistic regression analysis of individual blood miRNA and miRNA classifier of miR-193a-3p,
miR-23a and miR-338-5p








AUC 0.852 0.787 0.871 0.852 0.872 0.873 0.887
95% CI 0.768 - 0.935 0.685 - 0.889 0.800 - 0.942 0.770 - 0.935 0.798 - 0.946 0.803 - 0.942 0.821 - 0.953
Sensitivity (%) 100.0 94.3 81.4 74.3 94.3 81.4 80.0
Specificity (%) 56.2 53.1 75.0 81.2 65.6 75.0 84.4
Accuracy (%) 83.3 81.4 83.3 83.3 83.3 82.4 83.3
Youden’s Indexa 0.562 0.474 0.564 0.555 0.599 0.564 0.644
Cut-off value 0.346 0.502 0.640 0.745 0.474 0.636 0.728
aYouden’s Index = sensitivity + specificity - 1.
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-3p, miR-23a and miR-338-5p gave the best performance
and could be a potential biomarker in the detection of
CRC. The optimal cut-off value for sensitivity and specifi-
city was determined based on the highest Youden’s Index
in ROC curve analysis [48]. The triple classifier has a
stronger differentiation power than individual or double
combination of miRNAs. The classifier has an increased
area under ROC curve (AUC) of 0.887 (confidence interval
[CI]: 0.821 – 0.953) with 80.0% sensitivity, 84.4% specificity
and 83.3% accuracy, illustrating an improved diagnostic
value of these triple combination of miRNAs (Figure 4).
Discussion
MiRNA profiling studies in CRC and other diseases have
been vastly reported [35-38]. For instance, a recent tissue
miRNA profiling study by Piepoli et al. revealed a cluster of
dysregulated miRNAs (miR-195, miR-1280, miR-140-3p
and miR-1246) that could be used to distinguish between
colorectal and pancreatic cancers [49]. An investigation byFigure 4 ROC curve analysis using the triple miRNA classifier of miR-1
an AUC of 0.887 (95% CI: 0.821 - 0.953) with 80.0% sensitivity, 84.4% specifiHamfjord et al. using high throughput sequencing in paired
cancer tissues has reported 16 novel miRNAs (miR-490-
3p, miR-628-3p/-5p, miR-1297, miR-3151, miR-3163,
miR-3622a-5p, miR-3656, miR-105, miR-549, miR-1269,
miR-1827, miR-3144-3p, miR-3177, miR-3180-3p and
miR-4326) that have not been previously described in
CRC [50]. For blood-based miRNA profiling, Ahmed
et al. have identified a huge panel of differentially
expressed miRNAs in sporadic colon cancer patients [51].
Our data corresponded to theirs whereby an overlap of
certain markers (miR-130a, miR-150, miR-18b, miR-338,
miR-342 and miR92a) was observed in our blood array
study. Apart from that, Ng et al. have evaluated a panel of
95 miRNAs using real-time PCR-based array and plasma
miR-17-3p and miR-92 were shown to be significantly
expressed between the CRC cases and controls [52]. The
main aspect of our study is to determine whether the
circulating blood miRNAs are reflective of those in the
tissues. Therefore, we have investigated the correlation of
miRNA expressions between paired cancer tissue and93a-3p, miR-23a and miR-338-5p. The triple miRNA classifier yielded
city and 83.3% accuracy.
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miR-23a and miR-338-5p were significantly up-regulated
and positively correlated in both the tissue and blood
samples. The triple miRNA classifier identified in this
study was of high sensitivity (80.0%), specificity (84.4%)
and accuracy (83.3%) in defining CRC. The findings have
collectively implicated the potentiality of circulating blood
miRNAs as noninvasive biomarkers.
Mir-193a-3p is part of the miR-193 family, together with
miR-193a-5p and miR-193b. Nevertheless, the information
on miR-193a-3p is limited and its molecular mechanism
and role in carcinogenesis remain largely unknown. To our
knowledge, the present paper is the first report on the up-
regulation of miR-193a-3p in CRC. Although miR-193a-3p
has not been mentioned in CRC, its dysregulation has been
observed in pleural mesothelioma, ostersarcoma and oral
cancer, suggesting its impact in tumorigenesis [53-55].
Clearly, the role of miR-193a-3p in cancer needs to be
robustly investigated.
The role of miR-23a has been reported with varying con-
clusions. Recently, Jahid et al. revealed the function of miR-
23a in promoting the migration and invasion of CRC cells
and stem cells by down-regulating metastasis suppressor 1
(MTSS1) gene [56]. The finding is consistent with our study
whereby there is an increasing expression of miR-23a in the
more advanced tumors. A deep sequencing project using
serum samples has demonstrated a common up-regulation
of miR-23a in CRC and lung cancer patients [57]. An
in vitro study by Zhu et al. using gastric adenocarcinoma
cell line (MGC803) revealed a growth-promoting function
of miR-23a via regulation of interleukin-6 receptor (IL-6R)
gene [58]. Besides its individualistic function, miR-23a has
been shown to possess cooperative functions with miR-27a
and miR-24 [59]. The three miRNAs are derived from a
single primary transcript, located on chromosome 9q22.
These miRNAs have been bioinformatically predicted to
regulate cell proliferation and tissue development via Wnt
signaling pathway [60]. Wnt pathway is associated with
advancement of dysplasia in aberrant crypt foci and acts
as ‘gatekeeper’ in the initiation of adenoma-carcinoma
sequences in CRC. In addition, Rogler et al. found
miR-23b, a paralog of miR-23a to have an amplification
effect with miR-23a in regulating transforming growth
factor beta signaling by targeting SMAD genes [61]. This
is in support with our microarray and validation studies
whereby mir-23a and miR-23b were discovered to be
significantly up-regulated in both tissue and blood
samples. MiR-23a, together with miR-23b have been
reported to play certain roles in glutamine catabolism, cell
cycle regulation and glucose metabolism via regulation of
c-Myc gene [59,62]. On the contrary, miR-23a expression
has also been found to be repressed in several malignan-
cies, including oral squamous cell carcinoma and acute
promyelocytic leukemia [55,63]. The findings unveiled thepossibility of diverse miRNA functions in different cell
types and diseases.
MiR-338-3p and miR-338-5p are isoforms of miR-338. In
general, over-expression of miR-338 has been observed in
many cancers, namely CRC, hepatocellular carcinoma and
head and neck/oral cancer [64-66]. A tissue miRNA
profiling by Schetter et al. revealed 37 miRNAs, including
miR-338, to be differentially expressed in CRC tissues when
compared with paired noncancerous tissues [64]. In a
recent investigation on CRC recurrence-related miRNAs by
Ju et al., miR-338-5p was found to be significantly up-
regulated and positively correlated with cancer metastasis
[67]. Our findings corresponded to their study whereby
mir-338-5p expression was shown to be significantly higher
in the more advanced tumors.
An individual miRNA is definitely not an appealing
marker in discriminating CRC. The fact that miRNAs could
act as cell proliferating factors in certain cancers and apop-
totic factors in another has evoked the necessity of studying
their cooperative functions in order to provide a holistic
picture of miRNA regulations in cancer biology and
pathogenesis.
Conclusion
Dysregulations in circulating blood miRNAs are reflective
of those in colorectal tissues. The triple miRNA classifier of
miR-193a-3p, miR-23a and miR-338-5p appears to be a
potential blood biomarker for early detection of CRC. Our
study serves as an exploratory basis for further investigation
in larger prospective and randomized clinical studies with
higher number of samples from healthy controls and
patients of advanced adenoma and various stages of CRC.
A noninvasive miRNA screening assay using the triple
miRNA classifier could then be developed to identify
asymptomatic individuals with colorectal neoplasia prior to
more invasive colonoscopy examination.
Additional files
Additional file 1: Taqman 20X MicroRNA Assays. Reporter dye: FAM;
reporter quencher: NFQ (Applied Biosystems).
Additional file 2: (A) List of significantly deregulated miRNAs
(p < 0.05) from tissue miRNA array. MiRNA expression was shown as fold
change of cancer tissue versus adjacent normal mucosa. Positive value
denotes up-regulation and negative value denotes down-regulation.
(B) List of significantly deregulated miRNAs (p < 0.05) from blood miRNA
array. MiRNA expression was shown as fold change of TNM stages (I, II, III
and IV) versus control samples. Positive value denotes up-regulation and
negative value denotes down-regulation.
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